Cargando…
Evaluation of a COVID-19 IgM and IgG rapid test; an efficient tool for assessment of past exposure to SARS-CoV-2
COVID-19 is the most rapidly growing pandemic in modern time, and the need for serological testing is most urgent. Although the diagnostics of acute patients by RT-PCR is both efficient and specific, we are also crucially in need of serological tools for investigating antibody responses and assessin...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7178815/ https://www.ncbi.nlm.nih.gov/pubmed/32363011 http://dx.doi.org/10.1080/20008686.2020.1754538 |
_version_ | 1783525542892404736 |
---|---|
author | Hoffman, Tove Nissen, Karolina Krambrich, Janina Rönnberg, Bengt Akaberi, Dario Esmaeilzadeh, Mouna Salaneck, Erik Lindahl, Johanna Lundkvist, Åke |
author_facet | Hoffman, Tove Nissen, Karolina Krambrich, Janina Rönnberg, Bengt Akaberi, Dario Esmaeilzadeh, Mouna Salaneck, Erik Lindahl, Johanna Lundkvist, Åke |
author_sort | Hoffman, Tove |
collection | PubMed |
description | COVID-19 is the most rapidly growing pandemic in modern time, and the need for serological testing is most urgent. Although the diagnostics of acute patients by RT-PCR is both efficient and specific, we are also crucially in need of serological tools for investigating antibody responses and assessing individual and potential herd immunity. We evaluated a commercially available test developed for rapid (within 15 minutes) detection of SARS-CoV-2-specific IgM and IgG by 29 PCR-confirmed COVID-19 cases and 124 negative controls. The results revealed a sensitivity of 69% and 93.1% for IgM and IgG, respectively, based solely on PCR-positivity due to the absence of a serological gold standard. The assay specificities were shown to be 100% for IgM and 99.2% for IgG. This indicates that the test is suitable for assessing previous virus exposure, although negative results may be unreliable during the first weeks after infection. More detailed studies on antibody responses during and post infection are urgently needed. |
format | Online Article Text |
id | pubmed-7178815 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-71788152020-05-01 Evaluation of a COVID-19 IgM and IgG rapid test; an efficient tool for assessment of past exposure to SARS-CoV-2 Hoffman, Tove Nissen, Karolina Krambrich, Janina Rönnberg, Bengt Akaberi, Dario Esmaeilzadeh, Mouna Salaneck, Erik Lindahl, Johanna Lundkvist, Åke Infect Ecol Epidemiol Research Article COVID-19 is the most rapidly growing pandemic in modern time, and the need for serological testing is most urgent. Although the diagnostics of acute patients by RT-PCR is both efficient and specific, we are also crucially in need of serological tools for investigating antibody responses and assessing individual and potential herd immunity. We evaluated a commercially available test developed for rapid (within 15 minutes) detection of SARS-CoV-2-specific IgM and IgG by 29 PCR-confirmed COVID-19 cases and 124 negative controls. The results revealed a sensitivity of 69% and 93.1% for IgM and IgG, respectively, based solely on PCR-positivity due to the absence of a serological gold standard. The assay specificities were shown to be 100% for IgM and 99.2% for IgG. This indicates that the test is suitable for assessing previous virus exposure, although negative results may be unreliable during the first weeks after infection. More detailed studies on antibody responses during and post infection are urgently needed. Taylor & Francis 2020-04-14 /pmc/articles/PMC7178815/ /pubmed/32363011 http://dx.doi.org/10.1080/20008686.2020.1754538 Text en © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Hoffman, Tove Nissen, Karolina Krambrich, Janina Rönnberg, Bengt Akaberi, Dario Esmaeilzadeh, Mouna Salaneck, Erik Lindahl, Johanna Lundkvist, Åke Evaluation of a COVID-19 IgM and IgG rapid test; an efficient tool for assessment of past exposure to SARS-CoV-2 |
title | Evaluation of a COVID-19 IgM and IgG rapid test; an efficient tool for assessment of past exposure to SARS-CoV-2 |
title_full | Evaluation of a COVID-19 IgM and IgG rapid test; an efficient tool for assessment of past exposure to SARS-CoV-2 |
title_fullStr | Evaluation of a COVID-19 IgM and IgG rapid test; an efficient tool for assessment of past exposure to SARS-CoV-2 |
title_full_unstemmed | Evaluation of a COVID-19 IgM and IgG rapid test; an efficient tool for assessment of past exposure to SARS-CoV-2 |
title_short | Evaluation of a COVID-19 IgM and IgG rapid test; an efficient tool for assessment of past exposure to SARS-CoV-2 |
title_sort | evaluation of a covid-19 igm and igg rapid test; an efficient tool for assessment of past exposure to sars-cov-2 |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7178815/ https://www.ncbi.nlm.nih.gov/pubmed/32363011 http://dx.doi.org/10.1080/20008686.2020.1754538 |
work_keys_str_mv | AT hoffmantove evaluationofacovid19igmandiggrapidtestanefficienttoolforassessmentofpastexposuretosarscov2 AT nissenkarolina evaluationofacovid19igmandiggrapidtestanefficienttoolforassessmentofpastexposuretosarscov2 AT krambrichjanina evaluationofacovid19igmandiggrapidtestanefficienttoolforassessmentofpastexposuretosarscov2 AT ronnbergbengt evaluationofacovid19igmandiggrapidtestanefficienttoolforassessmentofpastexposuretosarscov2 AT akaberidario evaluationofacovid19igmandiggrapidtestanefficienttoolforassessmentofpastexposuretosarscov2 AT esmaeilzadehmouna evaluationofacovid19igmandiggrapidtestanefficienttoolforassessmentofpastexposuretosarscov2 AT salaneckerik evaluationofacovid19igmandiggrapidtestanefficienttoolforassessmentofpastexposuretosarscov2 AT lindahljohanna evaluationofacovid19igmandiggrapidtestanefficienttoolforassessmentofpastexposuretosarscov2 AT lundkvistake evaluationofacovid19igmandiggrapidtestanefficienttoolforassessmentofpastexposuretosarscov2 |